<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7428753\results\search\disease\results.xml">
  <result pre="Review Article Incidence and impact of cardiac arrhythmias in coronavirus" exact="disease" post="2019 (COVID-19): A systematic review and meta-analysis PranataRaymondraymond_pranata@hotmail.comraymond_pranata@hotmail.comaâˆ—HuangIanianhuang2108@gmail.comacRaharjoSunu Budhisunu.b.raharjo@gmail.comb[a],"/>
  <result pre="author. raymond_pranata@hotmail.comraymond_pranata@hotmail.com pmc-release: 2020-8-8collection: 2020epub: 2020-8-8205193198received: 2020-6-28rev-recd: 2020-7-17accepted: 2020-8-10(C) Indian" exact="Heart" post="Rhythm Society, 2020This is an open access article under"/>
  <result pre="occur in up to 44% of patients with severe coronavirus" exact="disease" post="2019 (COVID-19) and has been associated with an increased"/>
  <result pre="a systematic literature search from PubMed, SCOPUS, Europe PMC, Cochrane" exact="Central" post="Databases, and Google ScholarÂ +Â Preprint Servers. The primary"/>
  <result pre="Cochrane Central Databases, and Google ScholarÂ +Â Preprint Servers. The" exact="primary" post="endpoint of the study was poor outcomes including mortality,"/>
  <result pre="severe COVID-19, and the need for ICU care. Results A" exact="total" post="of 4 studies including 784 patients were analyzed. The"/>
  <result pre="4 studies including 784 patients were analyzed. The incidence of" exact="arrhythmia" post="in patients with COVID-19 was 19% (9â€&quot;28%; I2: 91.45)."/>
  <result pre="arrhythmia in patients with COVID-19 was 19% (9â€&quot;28%; I2: 91.45)." exact="Arrhythmia" post="occurred in 48% (38â€&quot;57%; I2: 48.08) of patients with"/>
  <result pre="85.33%) of patients without poor outcome. Patients with COVID-19 experiencing" exact="arrhythmia" post="had an increased risk of poor outcome (RR 7.96"/>
  <result pre="test showed indication of small-study effects (pÂ =Â 0.001). Conclusion" exact="Cardiac" post="arrhythmias were significantly associated with an increased risk of"/>
  <result pre="associated with an increased risk of poor outcome in COVID-19." exact="Arrhythmias" post="were observed in 19% of patients with COVID-19 and"/>
  <result pre="in 48% of patients with COVID-19 and poor outcomes. Keywords" exact="Arrhythmia" post="Cardiovascular Coronavirus COVID-19 Rhythm SARS-CoV-2 1 Introduction Coronavirus disease"/>
  <result pre="Keywords Arrhythmia Cardiovascular Coronavirus COVID-19 Rhythm SARS-CoV-2 1 Introduction Coronavirus" exact="disease" post="2019 (COVID-19) was declared pandemic, and at the time"/>
  <result pre="mild or no symptoms, some of them develop severe pneumonia," exact="acute" post="respiratory distress syndrome, multi-organ failure, and death. Factors such"/>
  <result pre="or no symptoms, some of them develop severe pneumonia, acute" exact="respiratory" post="distress syndrome, multi-organ failure, and death. Factors such as"/>
  <result pre="and death. Factors such as age, smoking, diabetes, hypertension, and" exact="cardiovascular" post="diseases are associated with severity and mortality in patients"/>
  <result pre="shown to be associated with an increased risk of ventricular" exact="arrhythmia" post="in patients with implantable cardiac defibrillators [8], indicating that"/>
  <result pre="in patients with implantable cardiac defibrillators [8], indicating that respiratory-borne" exact="infections" post="might also be related to cardiovascular manifestations. Severe acute"/>
  <result pre="[8], indicating that respiratory-borne infections might also be related to" exact="cardiovascular" post="manifestations. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has"/>
  <result pre="that respiratory-borne infections might also be related to cardiovascular manifestations." exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been shown"/>
  <result pre="respiratory-borne infections might also be related to cardiovascular manifestations. Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) has been shown to"/>
  <result pre="infections might also be related to cardiovascular manifestations. Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) has been shown to cause"/>
  <result pre="might also be related to cardiovascular manifestations. Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) has been shown to cause cardiac"/>
  <result pre="criteria This systematic review and meta-analysis included research articles on" exact="adult" post="COVID-19 patients that contain information on arrhythmia as a"/>
  <result pre="research articles on adult COVID-19 patients that contain information on" exact="arrhythmia" post="as a complication and contain a clinically validated definition"/>
  <result pre="study selection We systematically searched PubMed, SCOPUS, Europe PMC, Cochrane" exact="Central" post="Databases, and Google ScholarÂ +Â Preprint Servers with the"/>
  <result pre="extraction forms that included author, year, study design, age, sex," exact="cardiovascular" post="diseases, history of hypertension and diabetes mellitus, respiratory comorbidities,"/>
  <result pre="author, year, study design, age, sex, cardiovascular diseases, history of" exact="hypertension" post="and diabetes mellitus, respiratory comorbidities, antibiotics and antiviral use,"/>
  <result pre="study design, age, sex, cardiovascular diseases, history of hypertension and" exact="diabetes mellitus," post="respiratory comorbidities, antibiotics and antiviral use, glucocorticoid use, lymphopenia,"/>
  <result pre="age, sex, cardiovascular diseases, history of hypertension and diabetes mellitus," exact="respiratory" post="comorbidities, antibiotics and antiviral use, glucocorticoid use, lymphopenia, follow-up"/>
  <result pre="included studies will be performed using the Newcastle-Ottawa Scale. The" exact="primary" post="endpoint of the study was poor outcome, including mortality,"/>
  <result pre="including mortality, severe COVID-19, and the need for ICU care." exact="Severe" post="COVID-19 was defined as patients who had any of"/>
  <result pre="features at the time of admission or after admission: (1)" exact="respiratory" post="distress (â‰¥30 breaths per min); (2) oxygen saturation at"/>
  <result pre="(2) oxygen saturation at restÂ â‰¤Â 93%; (3) ratio of" exact="partial" post="pressure of arterial oxygen (PaO2) to fractional concentration of"/>
  <result pre="(fiO2)Â â‰¤Â 300Â mmHg; or (4) critical complication (respiratory failure," exact="septic shock," post="and multiple organ dysfunction/failure) [13]. 2.4 Statistical analysis The"/>
  <result pre="Meta-analysis of proportions was used to pool the incidence of" exact="arrhythmia" post="in the groups. Dichotomous variables were calculated to obtain"/>
  <result pre="Eggerâ€™s test. Random-effects meta-regression was performed for gender, hypertension, diabetes," exact="cardiovascular" post="diseases, cerebrovascular diseases, respiratory comorbidities, and lymphopenia. 3 Results"/>
  <result pre="was performed for gender, hypertension, diabetes, cardiovascular diseases, cerebrovascular diseases," exact="respiratory" post="comorbidities, and lymphopenia. 3 Results 3.1 Study selection We"/>
  <result pre="records and 509 remained after the removal of duplicates. A" exact="total" post="of 461 records were excluded after screening the titles"/>
  <result pre="of the following conditions: 1) there were no data on" exact="arrhythmia" post="as complication (nÂ =Â 43), and 2) arrhythmia was"/>
  <result pre="data on arrhythmia as complication (nÂ =Â 43), and 2)" exact="arrhythmia" post="was the baseline comorbidity, not an outcome (nÂ =Â"/>
  <result pre="[1.06, 1.56], pÂ =Â 0.01; I2: 49%, pÂ =Â 0.12)," exact="hypertension" post="(RR 2.38 [1.61, 3.51], pÂ 2: 69%, pÂ =Â"/>
  <result pre="(RR 2.38 [1.61, 3.51], pÂ 2: 69%, pÂ =Â 0.02)," exact="diabetes" post="(RR 2.60 [1.47, 4.61], pÂ =Â 0.001; I2: 45%,"/>
  <result pre="[1.47, 4.61], pÂ =Â 0.001; I2: 45%, pÂ =Â 0.14)," exact="cardiovascular" post="diseases (RR 3.51 [2.28, 5.42], pÂ 2: 0%, pÂ"/>
  <result pre="3.51 [2.28, 5.42], pÂ 2: 0%, pÂ =Â 0.55), and" exact="respiratory" post="comorbidities (RR 4.90 [2.12, 11.29], pÂ 2: 0%, pÂ"/>
  <result pre="0.75) were associated with poor outcome in this pooled analysis." exact="Cerebrovascular" post="diseases (RR 3.78 [0.72, 19.88], pÂ =Â 0.12; I2:"/>
  <result pre="the included studies. Data in the table were arranged as" exact="total" post="patients/prevalence (poor outcome group vs. without poor outcome group)."/>
  <result pre="Authors Study Design Samples Overall Age (Mean/Median) (years) Male (%)" exact="Hypertension" post="(%) Cardiovascular Comorbidities (%) Diabetes (%) Respiratory Comorbidities (%)"/>
  <result pre="Age (Mean/Median) (years) Male (%) Hypertension (%) Cardiovascular Comorbidities (%)" exact="Diabetes" post="(%) Respiratory Comorbidities (%) Hs-troponin I on Admission Cao"/>
  <result pre="(years) Male (%) Hypertension (%) Cardiovascular Comorbidities (%) Diabetes (%)" exact="Respiratory" post="Comorbidities (%) Hs-troponin I on Admission Cao J 2020"/>
  <result pre="the included studies. Data in the table were arranged as" exact="total" post="patients/prevalence (poor outcome group vs. without poor outcome group)."/>
  <result pre="100 vs. 98.8 Methylprednisolone: 64.7 vs 47.1 Hu L 2020" exact="Severe" post="COVID-19 7 28 daysMean Duration: Not ReportedSample: January 8,"/>
  <result pre="5.3 93.6 vs. 94.7 63.4 vs. 57.6 Zhang Guqin 2020" exact="Severe" post="COVID-19 7 Mean Duration: Not ReportedSample: January 2, 2020"/>
  <result pre="(Overall) 100 (Overall) Methylprednisolone: 45 (Overall) NOS: Newcastle-Ottawa Scale. 3.3" exact="Arrhythmia" post="incidence The incidence of arrhythmia in patients with COVID-19"/>
  <result pre="(Overall) NOS: Newcastle-Ottawa Scale. 3.3 Arrhythmia incidence The incidence of" exact="arrhythmia" post="in patients with COVID-19 was 19% (9â€&quot;28%; I2: 91.45,"/>
  <result pre="with COVID-19 was 19% (9â€&quot;28%; I2: 91.45, pÂ Fig.Â 2A)." exact="Arrhythmia" post="occurred in 48% (38â€&quot;57%; I2: 48.08, pÂ =Â 0.12)"/>
  <result pre="patients without poor outcome (Fig.Â 2C). Fig.Â 2 Incidence of" exact="arrhythmia" post="in COVID-19 patients with COVID 19. The incidence of"/>
  <result pre="arrhythmia in COVID-19 patients with COVID 19. The incidence of" exact="arrhythmia" post="is 19% (A). Arrhythmia occurs in 48% (B) of"/>
  <result pre="with COVID 19. The incidence of arrhythmia is 19% (A)." exact="Arrhythmia" post="occurs in 48% (B) of the patients with poor"/>
  <result pre="and 6% (C) of the patients without poor outcomes. 3.4" exact="Arrhythmia" post="and outcome of the COVID-19 Patients with COVID-19 experiencing"/>
  <result pre="Arrhythmia and outcome of the COVID-19 Patients with COVID-19 experiencing" exact="arrhythmia" post="had an increased risk of poor outcome (RR 7.96"/>
  <result pre="[3.26, 10.42], pÂ 2: 54%, pÂ =Â 0.11). Fig.Â 3" exact="Arrhythmia" post="and outcome of COVID-19. Patients with COVID-19 experiencing arrhythmia"/>
  <result pre="3 Arrhythmia and outcome of COVID-19. Patients with COVID-19 experiencing" exact="arrhythmia" post="have an increased risk of poor outcome. 3.5 Meta-regression"/>
  <result pre="increased risk of poor outcome. 3.5 Meta-regression The association between" exact="arrhythmia" post="and outcome in patients with COVID-19 did not vary"/>
  <result pre="significantly with age (pÂ =Â 0.840), male (pÂ =Â 0.220)," exact="hypertension" post="(pÂ =Â 0.977), cardiovascular diseases (pÂ =Â 0.848), diabetes"/>
  <result pre="=Â 0.840), male (pÂ =Â 0.220), hypertension (pÂ =Â 0.977)," exact="cardiovascular" post="diseases (pÂ =Â 0.848), diabetes (pÂ =Â 0.139), respiratory"/>
  <result pre="0.220), hypertension (pÂ =Â 0.977), cardiovascular diseases (pÂ =Â 0.848)," exact="diabetes" post="(pÂ =Â 0.139), respiratory comorbidities (pÂ =Â 0.729), and"/>
  <result pre="0.977), cardiovascular diseases (pÂ =Â 0.848), diabetes (pÂ =Â 0.139)," exact="respiratory" post="comorbidities (pÂ =Â 0.729), and lymphopenia (pÂ =Â 0.084)."/>
  <result pre="diabetes (pÂ =Â 0.139), respiratory comorbidities (pÂ =Â 0.729), and" exact="lymphopenia" post="(pÂ =Â 0.084). 3.6 Publication bias The funnel-plot analysis"/>
  <result pre="estimate. 4 Discussion This meta-analysis showed that the incidence of" exact="arrhythmia" post="was significantly higher in patients with poor outcomes, hence"/>
  <result pre="patients with poor outcomes, hence a marker of poor prognosis." exact="Cardiac" post="arrhythmias occurred frequently in patients with COVID-19, and the"/>
  <result pre="specify the types of arrhythmia. Hence, the specific types of" exact="arrhythmia" post="that increase mortality and severity of COVID-19 remain inconclusive."/>
  <result pre="and severity of COVID-19 remain inconclusive. Defining the types of" exact="arrhythmia" post="in patients with COVID-19 is important because of the"/>
  <result pre="associated with poor prognosis. Providing details on the type of" exact="arrhythmia" post="may help clinicians to discriminate the prognostic significance of"/>
  <result pre="in this pooled studies. These factors include gender, hypertension, diabetes," exact="cardiovascular" post="diseases, and respiratory comorbidities which is accordance to our"/>
  <result pre="studies. These factors include gender, hypertension, diabetes, cardiovascular diseases, and" exact="respiratory" post="comorbidities which is accordance to our previous meta-analyses assessing"/>
  <result pre="[7]]. We performed meta-regression and found that the association between" exact="arrhythmia" post="and poor outcome did not varied with the gender"/>
  <result pre="gender and other comorbidities, nevertheless the number of studies &amp;lt;10." exact="Arrhythmia" post="may be attributed to metabolic disarray, hypoxia, inflammation, or"/>
  <result pre="metabolic disarray, hypoxia, inflammation, or neurohormonal stress associated with SARS-CoV-2" exact="infection" post="[16]. Furthermore, COVID-19 induced coagulopathy may cause thrombosis leading"/>
  <result pre="neurohormonal stress associated with SARS-CoV-2 infection [16]. Furthermore, COVID-19 induced" exact="coagulopathy" post="may cause thrombosis leading to hypoxia [17,18]. Additionally, which"/>
  <result pre="with SARS-CoV-2 infection [16]. Furthermore, COVID-19 induced coagulopathy may cause" exact="thrombosis" post="leading to hypoxia [17,18]. Additionally, which patients often present"/>
  <result pre="[16]. Furthermore, COVID-19 induced coagulopathy may cause thrombosis leading to" exact="hypoxia" post="[17,18]. Additionally, which patients often present electrolyte abnormalities that"/>
  <result pre="by increase in cardiac biomarkers [20,21]. After activation of the" exact="viral" post="surface spike (S) protein of SARS-CoV-2 by the transmembrane"/>
  <result pre="and subsequent immune response may cause damage to the heart." exact="Myocardial inflammation," post="ion channel dysfunction, electrophysiological and structural remodeling associated with"/>
  <result pre="inflammation, ion channel dysfunction, electrophysiological and structural remodeling associated with" exact="viral" post="myocarditis has been shown to cause life-threatening arrhythmias [27]."/>
  <result pre="ion channel dysfunction, electrophysiological and structural remodeling associated with viral" exact="myocarditis" post="has been shown to cause life-threatening arrhythmias [27]. Evidence"/>
  <result pre="the possible role of cytokine storm in cardiac injury [28]." exact="Systemic" post="inflammation has been shown to prolong ventricular action potential"/>
  <result pre="potential duration through disturbance of the potassium channel [29]. Interleukin-6," exact="tumor" post="necrosis factor alpha, and interleukin-1 may prolong the action"/>
  <result pre="action potential duration through interplay with cardiomyocytes ion channels [30]." exact="Elevated" post="interleukin-6 during systemic inflammation may cause QT prolongation, which"/>
  <result pre="through interplay with cardiomyocytes ion channels [30]. Elevated interleukin-6 during" exact="systemic" post="inflammation may cause QT prolongation, which increases the risk"/>
  <result pre="prolong the QT interval [34] and increase the risk of" exact="cardiovascular" post="death [35]. The anti-malarial chloroquine is associated with prolonged"/>
  <result pre="inhibitors (PI) and usually used as 2nd-line drugs in treating" exact="HIV infection," post="is also recognized as arrhythmogenic and can prolong the"/>
  <result pre="associated with severe COVID-19, thus potentially affecting the association between" exact="arrhythmia" post="and severe COVID-19 [15]. A risk score developed by"/>
  <result pre="generalizable to other populations. Fourth, the number of studies were" exact="limited" post="and not divided into arrhythmias versus non-arrhythmias; hence, we"/>
  <result pre="are &amp;lt;10. Nevertheless, this study emphasizes the clinical importance of" exact="arrhythmia" post="in patients with COVID-19, and further studies should explore"/>
  <result pre="studies should explore cardiac arrhythmias in these patients. 5 Conclusion" exact="Cardiac" post="arrhythmias were significantly associated with an increased risk of"/>
  <result pre="associated with an increased risk of poor outcome in COVID-19." exact="Arrhythmias" post="were observed in 19% of patients with COVID-19 and"/>
  <result pre="study and drafted the manuscript. R. P. and I. H." exact="acquired" post="the data and drafted the manuscript. R. P. and"/>
  <result pre="Interests for this article. References References 1collab: World Health OrganizationCoronavirus" exact="disease" post="2019 (COVID-19) Situation Report â€&quot; 952020 2HuangI.LimM.A.PranataR.Diabetes mellitus is"/>
  <result pre="2HuangI.LimM.A.PranataR.Diabetes mellitus is associated with increased mortality and severity of" exact="disease" post="in COVID-19 pneumonia â€&quot; a systematic review, meta-analysis, and"/>
  <result pre="associated with increased mortality and severity of disease in COVID-19" exact="pneumonia" post="â€&quot; a systematic review, meta-analysis, and meta-regressionDiabetes Metab Syndr"/>
  <result pre="meta-regressionDiabetes Metab Syndr Clin Res Rev14202039540310.1016/j.dsx.2020.04.018 3PranataR.HuangI.LimM.A.WahjoepramonoE.J.JulyJ.Impact of cerebrovascular and" exact="cardiovascular" post="diseases on mortality and severity of COVID-19 â€&quot; systematic"/>
  <result pre="Dis202010494910.1016/j.jstrokecerebrovasdis.2020.104949 4PranataR.LimM.A.HuangI.RaharjoS.B.LukitoA.A.Hypertension is associated with increased mortality and severity of" exact="disease" post="in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regressionJÂ"/>
  <result pre="systematic review, meta-analysis and meta-regressionJÂ Renin-Angiotensin-Aldosterone Syst JRAAS21202014703203209268910.1177/1470320320926899 5PranataR.SoerotoA.Y.IanH.LimM.A.SantosoP.PermanaH.Effect of" exact="chronic" post="obstructive pulmonary disease and smoking on the outcome of"/>
  <result pre="meta-analysis and meta-regressionJÂ Renin-Angiotensin-Aldosterone Syst JRAAS21202014703203209268910.1177/1470320320926899 5PranataR.SoerotoA.Y.IanH.LimM.A.SantosoP.PermanaH.Effect of chronic obstructive" exact="pulmonary" post="disease and smoking on the outcome of COVID-19Int J"/>
  <result pre="and meta-regressionJÂ Renin-Angiotensin-Aldosterone Syst JRAAS21202014703203209268910.1177/1470320320926899 5PranataR.SoerotoA.Y.IanH.LimM.A.SantosoP.PermanaH.Effect of chronic obstructive pulmonary" exact="disease" post="and smoking on the outcome of COVID-19Int J Tubercul"/>
  <result pre="11WangD.HuB.HuC.ZhuF.LiuX.ZhangJ.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in wuhan, ChinaJAMA, J Am Med Assoc20201910.1001/jama.2020.1585 12CaoJ.TuW.-J.ChengW.YuL.LiuY.-K.HuX.Clinical features"/>
  <result pre="features and short-term outcomes of 102 patients with corona virus" exact="disease" post="2019 in wuhan, ChinaClin Infect Dis202010.1093/cid/ciaa243 13collab: World Health"/>
  <result pre="ChinaClin Infect Dis202010.1093/cid/ciaa243 13collab: World Health OrganizationReport of the WHO-China" exact="Joint" post="Mission on Coronavirus Disease( COVID-19 ). vol. 2019. n.d2019"/>
  <result pre="patients, health care workers, and health systems during the coronavirus" exact="disease" post="2019 (COVID-19) pandemicJÂ Am Coll Cardiol202010.1016/j.jacc.2020.03.031 17HuangI.PranataR.LimM.A.OehadianA.AlisjahbanaB.C-reactive protein, procalcitonin,"/>
  <result pre="a meta-analysisTher Adv Respir Dis14202010.1177/1753466620937175 18LimM.A.PranataR.HuangI.YonasE.SoerotoA.Y.SupriyadiR.Multiorgan failure with emphasis on" exact="acute" post="kidney injury and severity of COVID-19: systematic review and"/>
  <result pre="meta-analysisTher Adv Respir Dis14202010.1177/1753466620937175 18LimM.A.PranataR.HuangI.YonasE.SoerotoA.Y.SupriyadiR.Multiorgan failure with emphasis on acute" exact="kidney injury" post="and severity of COVID-19: systematic review and meta-analysisCan J"/>
  <result pre="injury and severity of COVID-19: systematic review and meta-analysisCan J" exact="Kidney" post="Heal Dis7202010.1177/2054358120938573 19LakkireddyD.R.ChungM.K.GopinathannairR.PattonK.K.GluckmanT.J.TuragamM.Guidance for cardiac electrophysiology during the coronavirus"/>
  <result pre="for cardiac electrophysiology during the coronavirus (COVID-19) pandemic from the" exact="heart" post="rhythm society COVID-19 task force; electrophysiology section of the"/>
  <result pre="heart rhythm society COVID-19 task force; electrophysiology section of the" exact="American" post="college of cardiology; and the electrocardiography and arrhythmias committee"/>
  <result pre="Rhythm202010.1016/j.hrthm.2020.03.028 20SantosoA.PranataR.WibowoA.Al-FarabiM.J.HuangI.AntariksaB.Cardiac injury is associated with mortality and critically ill" exact="pneumonia" post="in COVID-19: a meta-analysisAm J Emerg Med202010.1016/j.ajem.2020.04.052 21PranataR.HuangI.LukitoA.A.RaharjoS.B.Elevated N-terminal"/>
  <result pre="renin angiotensin system inhibitor on mortality in patients with coronavirus" exact="disease" post="2019 (COVID-19): a systematic review and meta-analysisDiabetes Metab Syndr"/>
  <result pre="novel coronavirus: implication for development of RBD protein as a" exact="viral" post="attachment inhibitor and vaccineCell Mol Immunol202010.1038/s41423-020-0400-4 25LiW.MooreM.J.VasllievaN.SuiJ.WongS.K.BerneM.A.Angiotensin-converting enzyme 2"/>
  <result pre="receptor for the SARS coronavirusNature426200345045410.1038/nature0214514647384 26ChenL.LiX.ChenM.FengY.XiongC.The ACE2 expression in human" exact="heart" post="indicates new potential mechanism of heart injury among patients"/>
  <result pre="ACE2 expression in human heart indicates new potential mechanism of" exact="heart" post="injury among patients infected with SARS-CoV-2Cardiovasc Res202010.1093/cvr/cvaa078 27TseG.YeoJ.M.ChanY.W.LaiE.T.H.L.YanB.P.What is"/>
  <result pre="infected with SARS-CoV-2Cardiovasc Res202010.1093/cvr/cvaa078 27TseG.YeoJ.M.ChanY.W.LaiE.T.H.L.YanB.P.What is the arrhythmic substrate in" exact="viral" post="myocarditis? Insights from clinical and animal studiesFront Physiol7201610.3389/fphys.2016.00308 28ClerkinK.J.FriedJ.A.RaikhelkarJ.SayerG.GriffinJ.M.MasoumiA.Coronavirus"/>
  <result pre="viral myocarditis? Insights from clinical and animal studiesFront Physiol7201610.3389/fphys.2016.00308 28ClerkinK.J.FriedJ.A.RaikhelkarJ.SayerG.GriffinJ.M.MasoumiA.Coronavirus" exact="disease" post="2019 (COVID-19) and cardiovascular diseaseCirculation120202004694110.1161/circulationaha.120.046941CIRCULATIONAHA 29LazzeriniP.E.CapecchiP.L.Laghi-PasiniF.Systemic inflammation and arrhythmic"/>
  <result pre="clinical and animal studiesFront Physiol7201610.3389/fphys.2016.00308 28ClerkinK.J.FriedJ.A.RaikhelkarJ.SayerG.GriffinJ.M.MasoumiA.Coronavirus disease 2019 (COVID-19) and" exact="cardiovascular" post="diseaseCirculation120202004694110.1161/circulationaha.120.046941CIRCULATIONAHA 29LazzeriniP.E.CapecchiP.L.Laghi-PasiniF.Systemic inflammation and arrhythmic risk: lessons from rheumatoid"/>
  <result pre="diseaseCirculation120202004694110.1161/circulationaha.120.046941CIRCULATIONAHA 29LazzeriniP.E.CapecchiP.L.Laghi-PasiniF.Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritisEur" exact="Heart" post="J2016ehw20810.1093/eurheartj/ehw208 30LazzeriniP.E.Laghi-PasiniF.BoutjdirM.CapecchiP.L.Cardioimmunology of arrhythmias: the role of autoimmune and"/>
  <result pre="rheumatoid arthritisEur Heart J2016ehw20810.1093/eurheartj/ehw208 30LazzeriniP.E.Laghi-PasiniF.BoutjdirM.CapecchiP.L.Cardioimmunology of arrhythmias: the role of" exact="autoimmune" post="and inflammatory cardiac channelopathiesNat Rev Immunol192019636410.1038/s41577-018-0098-z30552387 31LazzeriniP.E.Laghi-PasiniF.BertolozziI.MorozziG.LorenziniS.SimpaticoA.Systemic inflammation as"/>
  <result pre="risk factor in patients with torsades de pointesHeart10320171821182910.1136/heartjnl-2016-31107928490617 32HancoxJ.C.HasnainM.ViewegW.V.R.CrouseE.L.B.BaranchukA.Azithromycin ," exact="cardiovascular" post="risks , QTc interval prolongation , torsade de pointes"/>
  <result pre="prophylaxis of COVID-19 patients: a scientific statement from the Indian" exact="Heart" post="Rhythm SocietyIndian Pacing Electrophysiol J20202011712010.1016/j.ipej.2020.04.00332278018 34MosholderA.D.MathewJ.AlexanderJ.J.SmithH.NambiarS.Cardiovascular risks with azithromycin"/>
  <result pre="antibacterial drugsNÂ Engl J Med36820131665166810.1056/NEJMp130272623635046 35RayW.A.MurrayK.T.HallK.ArbogastP.G.SteinC.M.Azithromycin and the risk of" exact="cardiovascular" post="deathNÂ Engl J Med36620121881189010.1056/NEJMoa100383322591294 36collab: Pfizer LabsZithromax (azithromycin tablets)"/>
  <result pre="inhibitors (Lopinavir/Ritonavir) on the rat heartPLoS One8201310.1371/journal.pone.0073347 38LiuJ.ShahS.K.Basu-RayI.Garcia-DiazJ.KhalidK.SaeedM.QT prolongation in" exact="HIV-positive" post="patients: review articleIndian Heart J71201943443910.1016/j.ihj.2019.11.25932248914 39TisdaleJ.E.JaynesH.A.KingeryJ.R.MouradN.A.TrujilloT.N.OverholserB.R.Development and validation of"/>
  <result pre="rat heartPLoS One8201310.1371/journal.pone.0073347 38LiuJ.ShahS.K.Basu-RayI.Garcia-DiazJ.KhalidK.SaeedM.QT prolongation in HIV-positive patients: review articleIndian" exact="Heart" post="J71201943443910.1016/j.ihj.2019.11.25932248914 39TisdaleJ.E.JaynesH.A.KingeryJ.R.MouradN.A.TrujilloT.N.OverholserB.R.Development and validation of a risk score to"/>
  <result pre="Qual Outcomes6201347948710.1161/CIRCOUTCOMES.113.00015223716032 Acknowledgement None. Peer review under responsibility of Indian" exact="Heart" post="Rhythm Society."/>
 </snippets>
</snippetsTree>
